中文English
ISSN 1001-5256
CN 22-1108/R

留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

增强丙型肝炎病毒DNA疫苗免疫原性的策略

殷霄 文波 谭文杰

殷霄, 文波, 谭文杰. 增强丙型肝炎病毒DNA疫苗免疫原性的策略[J]. 临床肝胆病杂志, 2011, 27(1): 32-35.
引用本文: 殷霄, 文波, 谭文杰. 增强丙型肝炎病毒DNA疫苗免疫原性的策略[J]. 临床肝胆病杂志, 2011, 27(1): 32-35.
Yin Xiao, Wen Bo, Tan WenJie. Progress in the development and immunogenicity improvement of DNA vaccine against chronic HCV infection[J]. J Clin Hepatol, 2011, 27(1): 32-35.
Citation: Yin Xiao, Wen Bo, Tan WenJie. Progress in the development and immunogenicity improvement of DNA vaccine against chronic HCV infection[J]. J Clin Hepatol, 2011, 27(1): 32-35.

增强丙型肝炎病毒DNA疫苗免疫原性的策略

详细信息
  • 中图分类号: R392

Progress in the development and immunogenicity improvement of DNA vaccine against chronic HCV infection

  • 摘要:

    当前全世界有超过1.7亿慢性丙型肝炎(CHC)感染者,目前尚无有效的疫苗。最近丙型肝炎病毒(HCV)实验性疫苗的研制有不少进展。本文综述了增强HCV DNA疫苗免疫原性的策略及相关进展。

     

  • [1]Rehermann B, Nascimbeni M.Immunology of hepatitis B virus and hepatitis C virus infection[J].Nat Rev Immune, 2005, 5 (3) :215-229.
    [2]Mannes MP, Wedemeyer H, Cornberg M.Treating viral hepatitis C:efficacy, side effects, and complications[J].Gut, 2006, 55 (9) :1350-1359.
    [3]Houghton M, Abrignani S.Prospects for a vaccine against the hepatitis C virus[J].Nature, 2005, 436:961-966.
    [4]Sallberg M, Frelin L, Weiland O.DNA vaccine therapy for chronic hepatitis C virus (HCV) infection:immune control of a moving target[J].Expert Opin Biol Ther, 2009, 9 (7) :805-815.
    [5]Pierre L.Technological advances to increase immunogenicity of DNA vaccines[J].Vaccines, 2002, 1 (1) :85-93.
    [6]Sallberg MM, Frelin L, Diepolder H, et al.A first clinical trial of therapeutic vaccination using naked DNA delivered by in vivo electroporation shows antiviral effects in patients with chronic hepatitis C[C].Proceedings of the 44th Annual Meeting of the European Association for the Study of the Liver, 2009.
    [7]Alvarez-Lajonchere L, Shoukry NH, Gra B, et al.Immunogenicity of CIGB-230, a therapeutic DNA vaccine preparation, in HCV-chronically infected individuals in a Phase I clinical trial[J].J Viral Hepat, 2009, 16 (3) :156-167.
    [8] Large MK, Kittlesen DJ, Hahn YS.Suppression of host immune response by the core protein of hepatitis C virus:possible implications for hepatitis C virus persistence[J].J Immunol, 1999, 162 (2) :931-938.临床肝胆病杂志2011年第27卷第1期
    [9]Tokushige K, Wakita T, Pachuk C, et al.Expression and immune response to hepatitis C virus core DNA-based vaccine constructs[J].Hepatology, 1996, 24 (1) :14-20.
    [10]Lee SW, Cho JH, Lee KJ, et al.Hepatitis C virus envelope DNA-based immunization elicits humoral and cellular immune responses[J].Mol Cells, 1998, 8 (4) :444-451.
    [11]Isaguliants MG, Petrakova NV, Mokhonov VV, et al.DNA immunization efficiently targets conserved functional domains of protease and ATPase/helicase of nonstructural 3 protein (NS3) of human hepatitis C virus[J].Immunol Lett, 2003, 88 (1) :1-13.
    [12]Lang KA, Yan J, Draghia-Akli R, et al.Strong HCV NS3-and NS4A-specific cellular immune responses induced in mice and Rhesus macaques by a novel HCV genotype 1a/1b consensus DNA vaccine[J].Vaccine, 2008, 26 (49) :6225-6231.
    [13]Jens E, Jasperzu P, Michael G, et al.Proteins of the hepatitis C virus in a response against the nonstructural cellular and humoral immune genetic immunization generates[J].J Immune, 1998, 161 (9) :4917-4923.
    [14]Masalova OV, Lesnova EI, Pichugin AV, et al.The successful immune response against hepatitis C nonstructural protein 5A (NS5A) requires heterologous DNA/protein immunization[J].Vaccine, 2010, 28 (8) :1987-1996.
    [15]Frelin L, Alheim M, Chen A, et al.Low dose and gene gun immunization with a hepatitis C virus nonstructural (NS) 3 DNA-based vaccine containing NS4A inhibit NS3/4A-expressing tumors in vivo[J].Gene Ther, 2003, 10 (8) :686-699.
    [16]Gao M, Wang HP, Wang YN, et al.HCV-NS3 Th1 minigene vaccine based on invariant chain CLIP genetic substitution enhances CD4 (+) Th1 cell responses in vivo[J].Vaccine, 2006, 24 (26) :5491-5497.
    [17]Ma X, Forns X, Gutierrez R, et al.DNA-based vaccination against hepatitis C virus (HCV) :effect of expressing different forms of HCV E2 protein and use of CpG-optimized vectors in mice[J].Vaccine, 2002, 20 (27-28) :3263-3271.
    [18]Hong Yu, Lorne A.Babiuk, et al.Priming with CpG-enriched plasmid and boosting with protein formulated with CpG oligodeoxynucleotides and Quil A induces strong cellular and humoral immune responses to hepatitis C virus NS3[J].J Gen Virol, 2004, 85:1533-1543.
    [19]Frelin L, Alheim M, Chen A, et al.Low dose and gene gun immunization with a hepatitis C virus nonstructural (NS) 3 DNA-based vaccine containing NS4A inhibit NS3/4A-expressing tumors in vivo[J].Gene Ther, 2003, 10 (8) :686-699.
    [20]Ahlen G, Soderholm J, Tjelle T, et al.In Vivo Ele-ctroporation Enhances the Immunogenicity of Hepatitis C Virus Nonstructural 3/4A DNA by Increased Local DNA Uptake, Protein Expression, Inflammation, and Infiltration of CD3+T Cells[J].J Immunol, 2007, 179 (7) :4741-4753.
    [21]Schwendener RA, Ludewig B, Cerny A, et al.Liposome-based vaccines[J].Methods Mol Biol, 2010, 605:163-175.
    [22]Desjardins D, Huret C, Dalba C, et al.Recombinant retrov-irus-like particle forming DNA vaccines in prime-boost immunization and their use for hepatitis C virus vaccine development[J].J Gene Med, 2009, 11 (4) :313-325.
    [23]Folgori A, Capone S, Ruggeri L, et al.A T-cell HCV vaccine eliciting effective immunity against heterologous virus challenge in chimpanzees[J].Nat Med, 2006, 12 (2) :190-197.
  • 加载中
计量
  • 文章访问数:  2986
  • HTML全文浏览量:  15
  • PDF下载量:  899
  • 被引次数: 0
出版历程
  • 出版日期:  2011-01-20
  • 分享
  • 用微信扫码二维码

    分享至好友和朋友圈

目录

    /

    返回文章
    返回